期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童白血病和淋巴瘤靶向治疗研究进展 被引量：1

Advances in targeted therapy of childhood for leukemia and lymphoma
原文传递
导出
摘要 靶向治疗因其特异性高和毒副作用小等优势,在白血病及淋巴瘤等儿科常见血液系统肿瘤治疗中具有重要作用。单克隆抗体如CD20单克隆抗体(利妥昔单抗)治疗B细胞淋巴瘤,酪氨酸激酶抑制剂(TKI)如BCR/ABL抑制剂(甲磺酸伊马替尼)治疗慢性粒细胞白血病(CML),泛素-蛋白酶体抑制剂治疗复发急性白血病等疗效显著的品种,以及新型靶向治疗如抗体偶联药物等在儿科临床中的应用均为临床关注热点。本文简要综述儿童白血病和淋巴瘤靶向治疗药物的临床评价及其研究进展。 Targeted therapy plays an important role in the treatment of leukemia and lymphoma with its higher specificity and fewer adverse reactions. The remarkable outcomes including CD20 monoclonal antibody （rituximab） in B-cell lymphoma, BCR/ABL inhibitor （imatinib mesylate） in CML and ubiquitin proteasome inhibitor in relapsed acute leukemia have been found. In addition, new targeted therapy such as antibody-drug conjugates also has been found good results in clinics. Targeted therapy has become a hotspot in the treatment of hematological malignancy. This review describes advances in targeted therapy of childhood for leukemia and lymphoma.
作者 王苹 翟晓文
机构地区 复旦大学附属儿科医院血液科
出处 《世界临床药物》 CAS 2015年第5期298-304,共7页 World Clinical Drug
基金 上海市人才发展基金(2012051)
关键词 儿童 白血病 淋巴瘤 靶向治疗 childhood leukemia lymphoma targeted therapy
分类号 R979.1 [医药卫生—药品] R552 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献43

  • 1胡亚美,江载芳.诸福棠实用儿科学:下册[M].7版.北京:人民卫生出版社,2002:1809.
  • 2Hunger SP, Raetz EA, Loh ML, et al. Improving outcomes for high-risk ALL: translating new discoveries into clinical care [J]. Pediatr Blood Cancer, 2011, 56 (6): 984-993.
  • 3Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group [J]. J Clin Oncol, 2012, 30 (14) :1663-1669.
  • 4Goldman S, Smith L,Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/ leukaemia: a Children's Oncology Group Report [J]. Br J Haematol, 2014, 167 (3) : 394-401.
  • 5Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group [J]. Pediatr Blood Cancer, 2011, 57 (1) : 56-62.
  • 6Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabEJl. Haematologica, 2014, 99(7): 1212-1219.
  • 7Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells [J]. J Clin Invest, 2009, 119 (8) : 2143-2159.
  • 8Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia [J]. J Clin Oncol, 2010, 28 (19): 3115-3121.
  • 9Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy [Jl. Expert Opin Biol Ther, 2008, 8 (8) : 1151-1158.
  • 10Herter S, Herring F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models [J]. Mol Cancer Ther, 2013, 12 (10): 2031-2042.

二级参考文献67

  • 1王永韧,陆化,刘澎,张建富,仇海荣,吴雨洁,杨慧,李建勇.急性白血病患者中ICAM-1和VCAM-1的表达及意义[J].江苏医药,2007,33(8):765-767. 被引量：7
  • 2Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med, 1999; 5:412 - 417
  • 3Wissink S, van-de-Stolpe A, Caldenhoven E, et al. NF-kappa B/ Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells. Immunobiology, 1997 ; 198:50 - 64
  • 4Jobin C, Hellerbrand C, Licato LL, et al. Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 ( ICAM-1 ) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut, 1998 ; 42:779 - 787
  • 5Guzman ML, Neering S J, Upchurch D, et al. Nuclear factorkappa B is constitutively activated in primitive human acute myelogenous leukemia ceils. Blood, 2001 ; 98:2301 -2307
  • 6Rajkmar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol, 2005 ; 23:630 -639
  • 7Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors [J].Cun" Opin Immunol, 2009,21:215-223.
  • 8Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Batv virus spe- cific cytotoxic T lymphocytes expressing the anti-CD30zeta arti- ficial chimeric T-cell receptor for immunotherapy of Hodgkin disease [J].Blood,2007,110(7):2620-2630.
  • 9Daly T, Royal RE, Kershaw MH, et al. Recognition of human co- lon cancer by T cells transduced with a chimeric receptor gene [J].Cancer Gene Ther,2000,7:284-291.
  • 10Brentjens R J, Hollyman DR, WeissM, et al. Treatment of chron- ic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial [J].Mol Ther,2010, 18(4) :666-674.

共引文献10

同被引文献5

引证文献1

二级引证文献5

世界临床药物
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部